Patents by Inventor Pierre-Jean Colson

Pierre-Jean Colson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • JAK kinase inhibitor compounds for treatment of respiratory disease
    Patent number: 11718616
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: August 8, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Anne-Marie Beausoleil, Gary E. L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Pierre-Jean Colson, Gene Timothy Fass, Miroslav Rapta, Noah Benjamin, Marta Dabros, Venkat R. Thalladi
  • JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE
    Publication number: 20220306624
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: March 7, 2022
    Publication date: September 29, 2022
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Anne-Marie Beausoleil, Gary E.L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Pierre-Jean Colson, Gene Timothy Fass, Miroslav Rapta, Noah Benjamin, Marta Dabros, Venkat R. Thalladi
  • Process for preparing JAK inhibitors and intermediates thereof
    Patent number: 10844057
    Abstract: The invention is directed to a process for preparing compounds which are useful as intermediates for the preparation of medicinal agents having inhibitory activity for JAK.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: November 24, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Pierre-Jean Colson, Gene Timothy Fass
  • PROCESS FOR PREPARING JAK INHIBITORS AND INTERMEDIATES THEREOF
    Publication number: 20200071324
    Abstract: The invention is directed to a process for preparing compounds which are useful as intermediates for the preparation of medicinal agents having inhibitory activity for JAK.
    Type: Application
    Filed: September 3, 2019
    Publication date: March 5, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Pierre-Jean Colson, Gene Timothy Fass
  • Crystalline forms of an 8-azabicyclo[3.2.1]octane compound
    Patent number: 10426766
    Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: October 1, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Sean Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
  • CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND
    Publication number: 20180200246
    Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
    Type: Application
    Filed: March 13, 2018
    Publication date: July 19, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Sean Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
  • Crystalline forms of an 8-azabicyclo[3.2.1]octane compound
    Patent number: 9949963
    Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: April 24, 2018
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Sean Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
  • JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease
    Publication number: 20170121327
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: November 2, 2016
    Publication date: May 4, 2017
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Anne-Marie Beausoleil, Gary E. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Pierre-Jean Colson, Gene Timothy Fass, Miroslav Rapta, Noah Benjamin, Marta Dabros, Venkat R. Thalladi
  • CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND
    Publication number: 20160287572
    Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
    Type: Application
    Filed: February 10, 2016
    Publication date: October 6, 2016
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Sean Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
  • Crystalline forms of an 8-azabicyclo[3.2.1]octane compound
    Patent number: 9290491
    Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: March 22, 2016
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Sean M. Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
  • Process for preparing biphenyl imidazole compounds
    Patent number: 9221763
    Abstract: The invention provides processes for preparing intermediates useful for preparing compounds of the formula: or a salt thereof, where R1-3 are as defined in the specification.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: December 29, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventor: Pierre-Jean Colson
  • CRYSTALLINE FORMS OF A 3-[2-METHANESULFONYL-1-(4-TRIFLUOROMETHYL-PHENOXY)ETHYL]PYRROLIDINE COMPOUND
    Publication number: 20150141483
    Abstract: The invention provides crystalline hydrochloride salts of (S)-3-[(S)-2-methanesulfonyl-1-(4-trifluoromethylphenoxy)ethyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salts, processes and intermediates for preparing the crystalline salts, and methods of using the crystalline salts to treat diseases.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 21, 2015
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Pierre-Jean Colson, Timothy Fass, Venkat R. Thalladi
  • Process for preparing a biphenyl-2-ylcarbamic acid
    Patent number: 9035061
    Abstract: The invention provides a process of preparing an intermediate useful in the synthesis of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and a process of preparing a crystalline freebase of the ester.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: May 19, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventor: Pierre-Jean Colson
  • CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND
    Publication number: 20150073014
    Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
    Type: Application
    Filed: July 16, 2014
    Publication date: March 12, 2015
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Sean M. Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
  • 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
    Patent number: 8969370
    Abstract: The invention provides 3-carboxypropyl-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, and R6 are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: March 3, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Sean G. Trapp, Michael R. Leadbetter, Daniel D. Long, Pierre-Jean Colson, Miroslav Rapta, Ying Yu
  • Crystalline forms of a 3-[2-methanesulfonyl-1-(4-trifluoromethyl-phenoxy)ethyl]pyrrolidine compound
    Patent number: 8969403
    Abstract: The invention provides crystalline hydrochloride salts of (S)-3-[(S)-2-methanesulfonyl-1-(4-trifluoromethylphenoxy)ethyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salts, processes and intermediates for preparing the crystalline salts, and methods of using the crystalline salts to treat diseases.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: March 3, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Pierre-Jean Colson, Timothy Fass, Venkat R. Thalladi
  • PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS
    Publication number: 20150038725
    Abstract: The invention provides processes for preparing intermediates useful for preparing compounds of the formula: or a salt thereof, where R1-3 are as defined in the specification.
    Type: Application
    Filed: October 16, 2014
    Publication date: February 5, 2015
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Weijiang Zhang, Pierre-Jean Colson, Gene Timothy Fass
  • Process for preparing biphenyl imidazole compounds
    Patent number: 8889882
    Abstract: The invention provides processes for preparing intermediates useful for preparing compounds of the formula: or a salt thereof, where R1-3 are as defined in the specification.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: November 18, 2014
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Weijiang Zhang, Pierre-Jean Colson, Gene Timothy Fass
  • 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20140329845
    Abstract: The invention provides 3-carboxypropyl-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, and R6 are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: March 4, 2014
    Publication date: November 6, 2014
    Applicant: THERAVANCE, INC.
    Inventors: Sean G. Trapp, Michael R. Leadbetter, Daniel D. Long, Pierre-Jean Colson, Miroslav Rapta, Ying Yu
  • Crystalline forms of an 8-azabicyclo[3.2.1]octane compound
    Patent number: 8816091
    Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: August 26, 2014
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Sean Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson